Switzerland· 21871001
Atarax, comprimés pelliculés
A hydroxyzine product, registered in Switzerland by UCB-Pharma SA and dispensed under Swissmedic category B. The same ATC class is registered in 15 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Hydroxyzine is registered in 15 of 19 countries.
Countries holding a registration under ATC N05BB01 (hydroxyzine), each read from that country’s own register.
- This record: Switzerland
- 8 of them publish a price we can compare per daily dose
Hydroxyzine · ATC N05BB01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of hydroxyzine costs, country by country.
Normalised to the WHO defined daily dose (75 mg), the median price runs from $0.16 in United States to $1.68 in Switzerland — a ×11 gap.
- Switzerland: $1.68 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Hydroxyzine · price per daily dose (75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.68
- US United States$0.16 (acquisition cost)
The record
At a glance
- Manufacturer
- UCB-Pharma SA
- Country
- Switzerland (CH)
- ATC code
- N05BB01
- ATC class
- Hydroxyzine
- Defined daily dose
- 75 mg, O
- Swissmedic category
- B
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
410 interactions on record for hydroxyzine.
Graded by severity as the source publishes them — 46 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Hydroxyzine · interactions on record
410 records
- 46 severe
- 199 moderate
- 5 minor
- 160 info
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- Potassium chlorideA12BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N05BB01
Hydroxyzine, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dbc3e45e-0955-4fa1-936c-6a728a6fa437 GET /v1/drugs/dbc3e45e-0955-4fa1-936c-6a728a6fa437?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about hydroxyzine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.